Found: 17
Select item for more details and to access through your institution.
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.
- Published in:
- Journal of Personalized Medicine, 2021, v. 11, n. 5, p. 355, doi. 10.3390/jpm11050355
- By:
- Publication type:
- Article
Infection risk and antimicrobial prophylaxis in bendamustine‐treated patients with indolent non‐Hodgkin lymphoma: An Australasian Lymphoma Alliance study.
- Published in:
- British Journal of Haematology, 2024, v. 205, n. 1, p. 146, doi. 10.1111/bjh.19407
- By:
- Publication type:
- Article
New standards of care for treatment of diffuse large B‐cell lymphoma.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 4, p. 1132, doi. 10.1111/bjh.19295
- By:
- Publication type:
- Article
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B‐cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 2, p. 174, doi. 10.1111/bjh.16064
- By:
- Publication type:
- Article
Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
A consensus statement on the use of biosimilar medicines in hematology in Australia.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2020, v. 16, n. 4, p. 211, doi. 10.1111/ajco.13337
- By:
- Publication type:
- Article
Cold agglutinin disease complicated by acrocyanosis and necrosis.
- Published in:
- 2017
- By:
- Publication type:
- Case Study
Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
- Published in:
- Internal Medicine Journal, 2024, v. 54, n. 6, p. 1017, doi. 10.1111/imj.16390
- By:
- Publication type:
- Article
Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
- Published in:
- Internal Medicine Journal, 2022, v. 52, n. 9, p. 1624, doi. 10.1111/imj.15658
- By:
- Publication type:
- Article
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience.
- Published in:
- Internal Medicine Journal, 2021, v. 51, n. 11, p. 1825, doi. 10.1111/imj.14965
- By:
- Publication type:
- Article
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-07551-w
- By:
- Publication type:
- Article
Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.
- Published in:
- Nature Communications, 2017, v. 8, n. 3, p. 14581, doi. 10.1038/ncomms14581
- By:
- Publication type:
- Article
IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S406, doi. 10.1016/S2152-2650(21)01916-9
- By:
- Publication type:
- Article
Poster: IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S245, doi. 10.1016/S2152-2650(21)01540-8
- By:
- Publication type:
- Article
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 6, p. 761, doi. 10.1007/s11523-021-00849-8
- By:
- Publication type:
- Article